Industry Assignment 3
Brandon Ness
Muscle Pharm Corp.
The 5-year chart for Muscle Pharm is flawed because they didn't have an IPO until late 2011, so I used a 2-year time period for comparison.
Muscle Pharm Corp.(MSLP)Watchlist 13.75+0.14+1.03%oTC Markets-As of 02:28pm EDT
Beat the market Get the app
1d 5d
1m 3m 6m YTD 1y2y5y10yMax Custom
+Indicator
Comparison
Reset
Go To Symbol
MSLP 13.75
DJI16.738.17
GSPC1.957.42
75%
13.55 Close 13.75 Low 13.55 High 14 14.4K
1.78% 50%
38.41 27.84%]
0%
-25%
-50%
-75% Oct 5,201
MSLP outperformed both the Dow and StiP indexes over a two-year period. MSLP stock increased 61.78%, while the Dow and StiP increased 27.84% and 38.41%, respectively. 2. Muscle Pharm does not pay a dividend 3. Muscle Pharm's market cap is 153.01 million. 4. Revenue has been increasing each year and the company has been making smarter investments and business decisions than they did in the beginning, so I feel there is room for growth, and I would want to buy this stock. 5. The trends that influence my decision to buy are: a substantial yearly increase in revenue and a substantial increase in gross profit. 6. In 2012, Muscle Pharm's reported a 290% increase in net sales from 2011. Founder and CE0 Brad Pyatt commented that the focus in 2012 was on brand awareness and increasing sales. In 2013, they planned to build further on said issues while also focusing on profitability. With a revamped balance sheet due to $18 million in equity financing, he foresees(saw) an encouraging future for the compan